Metraipolis › archive › dc_cfd4ff5ffcc1

Post-marketing safety profile and clinical prioritization of adverse events with avacopan in ANCA-associated vasculitis: a FAERS pharmacovigilance analysis — Europe PMC PMID:41131744

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41131744
DOI: 10.1080/0886022x.2025.2568971
License (as archived): solo-consultazione
Archived: 2026-11-09T03:17:16.185Z
SHA-256 of the archived text: 59a35c7cd5f168f9c12b7b740d12957e54d916c0a7f0ba2565abc8ebf41795c0
Stable URL of this page: https://metraipolis.com/documento/dc_cfd4ff5ffcc1

How to cite

Post-marketing safety profile and clinical prioritization of adverse events with avacopan in ANCA-associated vasculitis: a FAERS pharmacovigilance analysis — Europe PMC PMID:41131744 — Europe PMC (en), https://europepmc.org/article/MED/41131744 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cfd4ff5ffcc1 (Metraipolis archive dc_cfd4ff5ffcc1, sha256 59a35c7cd5f168f9c12b7b740d12957e54d916c0a7f0ba2565abc8ebf41795c0)

BibTeX

@misc{dccfd4ff5ffcc1,
  title = {Post-marketing safety profile and clinical prioritization of adverse events with avacopan in ANCA-associated vasculitis: a FAERS pharmacovigilance analysis — Europe PMC PMID:41131744},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41131744},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cfd4ff5ffcc1; sha256 59a35c7cd5f168f9c12b7b740d12957e54d916c0a7f0ba2565abc8ebf41795c0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41131744. Agents can read the archived copy with the MCP tool read_document.